These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 8274605)
1. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Zaia JA Clin Infect Dis; 1993 Nov; 17 Suppl 2():S392-9. PubMed ID: 8274605 [TBL] [Abstract][Full Text] [Related]
2. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360 [TBL] [Abstract][Full Text] [Related]
3. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Bailey TC; Ettinger NA; Storch GA; Trulock EP; Hanto DW; Dunagan WC; Jendrisak MD; McCullough CS; Kenzora JL; Powderly WG Am J Med; 1993 Sep; 95(3):273-8. PubMed ID: 8396320 [TBL] [Abstract][Full Text] [Related]
4. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Goodrich JM; Boeckh M; Bowden R Clin Infect Dis; 1994 Aug; 19(2):287-98. PubMed ID: 7986901 [TBL] [Abstract][Full Text] [Related]
5. Cytomegaloviral virus infection in bone marrow transplantation recipients: strategies for prevention and treatment. Holland HK; Saral R Support Care Cancer; 1993 Sep; 1(5):245-9. PubMed ID: 8156234 [TBL] [Abstract][Full Text] [Related]
6. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. Bailey TC; Trulock EP; Ettinger NA; Storch GA; Cooper JD; Powderly WG J Infect Dis; 1992 Mar; 165(3):548-52. PubMed ID: 1311352 [TBL] [Abstract][Full Text] [Related]
7. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Torres-Madriz G; Boucher HW Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557 [TBL] [Abstract][Full Text] [Related]
8. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Hebart H; Kanz L; Jahn G; Einsele H Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790 [TBL] [Abstract][Full Text] [Related]
9. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394 [TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation. Tsinontides AC; Bechtel TP Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411 [TBL] [Abstract][Full Text] [Related]
11. [Cytomegalovirus infection in transplant recipients]. Gondo H Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685 [TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. Schmidt GM; Horak DA; Niland JC; Duncan SR; Forman SJ; Zaia JA N Engl J Med; 1991 Apr; 324(15):1005-11. PubMed ID: 1848679 [TBL] [Abstract][Full Text] [Related]
13. Comparison of ganciclovir- and immune globulin-containing regimens in preventing cytomegalovirus infection in patients with renal transplants. Walton T; Sankari B; Wyner L Am J Health Syst Pharm; 1999 Sep; 56(18):1831-4. PubMed ID: 10511232 [TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infections after allogeneic bone marrow transplantation. Winston DJ; Ho WG; Champlin RE Rev Infect Dis; 1990; 12 Suppl 7():S776-92. PubMed ID: 2173107 [TBL] [Abstract][Full Text] [Related]
15. Treatment and prophylaxis of cytomegalovirus disease. Levinson ML; Jacobson PA Pharmacotherapy; 1992; 12(4):300-18. PubMed ID: 1325636 [TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Boeckh M; Nichols WG; Papanicolaou G; Rubin R; Wingard JR; Zaia J Biol Blood Marrow Transplant; 2003 Sep; 9(9):543-58. PubMed ID: 14506657 [TBL] [Abstract][Full Text] [Related]
17. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
18. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472 [TBL] [Abstract][Full Text] [Related]
19. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341 [TBL] [Abstract][Full Text] [Related]
20. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]